Novonesis (CPSE:NSIS B) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

NSIS B Overzicht aandelen

NSIS B fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	3/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

De winst zal naar verwachting met 29.13% per jaar groeien

Risicoanalyse

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

Grote eenmalige posten die de financiële resultaten beïnvloeden

Winstmarges (9.3%) zijn lager dan vorig jaar (19.3%)

Novonesis A/S Concurrenten

Asian Paints

NSEI:ASIANPAINT

₹3.1t

Wanhua Chemical Group

SHSE:600309

CN¥286.7b

PPG Industries

NYSE:PPG

US$30.9b

DuPont de Nemours

NYSE:DD

US$37.2b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Novonesis
Historische aandelenkoersen
Huidige aandelenkoers	DKK 473.60
52 Week Hoogtepunt	DKK 485.90
52 Week Laag	DKK 274.60
Bèta	0.52
11 maand verandering	1.20%
3 maanden verandering	9.81%
1 Jaar Verandering	64.44%
33 jaar verandering	8.95%
5 jaar verandering	66.64%
Verandering sinds IPO	1,361.73%

Recent nieuws en updates

Recent updates

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

Sep 27

An Intrinsic Calculation For Novozymes A/S (CPH:NZYM B) Suggests It's 22% Undervalued

Sep 05

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

Sep 13

The Returns On Capital At Novozymes (CPH:NZYM B) Don't Inspire Confidence

Aug 29

Estimating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Jul 13

Here's Why Novozymes (CPH:NZYM B) Can Manage Its Debt Responsibly

Jun 13

Here's What's Concerning About Novozymes' (CPH:NZYM B) Returns On Capital

May 29

Estimating The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)

Apr 12

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Mar 01

Rendement voor aandeelhouders

	NSIS B	DK Chemicals	DK Markt
7D	-0.6%	2.0%	-3.2%
1Y	64.4%	17.6%	21.8%

Rendement versus industrie: NSIS B overtrof de Danish Chemicals industrie, die het afgelopen jaar een rendement 17.8 % opleverde.

Rendement versus markt: NSIS B overtrof de Danish markt, die het afgelopen jaar een rendement opleverde van 19.8 %.

Prijsvolatiliteit

Is NSIS B's price volatile compared to industry and market?
NSIS B volatility
NSIS B Average Weekly Movement	2.4%
Chemicals Industry Average Movement	5.0%
Market Average Movement	4.3%
10% most volatile stocks in DK Market	8.9%
10% least volatile stocks in DK Market	2.5%

Stabiele aandelenkoers: NSIS B heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 2% ) van NSIS B is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1925	10,452	Ester Baiget	www.novonesis.com

Novonesis A/S produceert en verkoopt industriële enzymen, micro-organismen en probiotica in Denemarken, de rest van Europa, Noord-Amerika, Azië-Pacific, het Midden-Oosten, Afrika en Latijns-Amerika. Het bedrijf biedt eiwitoplossingen voor de voedingsmiddelen- en drankenindustrie. Het biedt ook industriële hygiëne, afvoeropeners, harde oppervlakken, medische reiniging, septische tanks, vaatwas en professionele wasdiensten.

Novonesis A/S Samenvatting

Hoe verhouden de winst en inkomsten van Novonesis zich tot de beurswaarde?
NSIS B fundamentele statistieken
Marktkapitalisatie	DKK 219.95b
Inkomsten(TTM)	DKK 2.11b
Inkomsten(TTM)	DKK 22.72b

104.3x

Koers/Winstverhouding

9.7x

P/S-verhouding

Is NSIS B overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
NSIS B resultatenrekening (TTM)
Inkomsten	€3.04b
Kosten van inkomsten	€1.62b
Brutowinst	€1.42b
Overige uitgaven	€1.14b
Inkomsten	€282.79m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

Nov 07, 2024

Winst per aandeel (EPS)	0.61
Brutomarge	46.66%
Nettowinstmarge	9.29%
Schuld/Eigen Vermogen Verhouding	18.1%

Hoe presteerde NSIS B op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

0.8%

Huidig dividendrendement

108%

Uitbetalingsratio

NSIS B Overzicht aandelen

Beloningen

Risicoanalyse

Novonesis A/S Concurrenten

NSEI:ASIANPAINT

₹3.1t

SHSE:600309

CN¥286.7b

NYSE:PPG

US$30.9b

NYSE:DD

US$37.2b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Consensus EPS estimates increase by 11%

Consensus EPS estimates fall by 20%

First half 2024 earnings released: EPS: €0.14 (vs €0.67 in 1H 2023)

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Consensus EPS estimates increase by 13%, revenue downgraded

Novonesis Provides Sales Guidance for the Year 2024

Recent updates

Consensus EPS estimates increase by 11%

Consensus EPS estimates fall by 20%

First half 2024 earnings released: EPS: €0.14 (vs €0.67 in 1H 2023)

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Consensus EPS estimates increase by 13%, revenue downgraded

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Upcoming dividend of kr.2.00 per share

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Consensus EPS estimates increase by 14%

Full year 2023 earnings: Revenues in line with analyst expectations

New major risk - Shareholder dilution

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment

Novozymes Launches ProSilience™ HU58

Third quarter 2023 earnings: Revenues exceed analyst expectations

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

An Intrinsic Calculation For Novozymes A/S (CPH:NZYM B) Suggests It's 22% Undervalued

Now 21% undervalued after recent price drop

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Novozymes A/S Announces Change to the Executive Leadership Team

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Is Now The Time To Put Novozymes (CPH:NZYM B) On Your Watchlist?

Upcoming dividend of kr.6.00 per share at 1.8% yield

Novozymes' (CPH:NZYM B) Profits Appear To Have Quality Issues

Independent Chairman recently bought kr.1.0m worth of stock

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Novozymes A/S Provides Earnings Guidance for the Year 2023

Full year 2022 earnings: Revenues in line with analyst expectations

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Is Novozymes (CPH:NZYM B) Using Too Much Debt?

Investor sentiment deteriorated over the past week

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Returns On Capital At Novozymes (CPH:NZYM B) Paint A Concerning Picture

Less than half of directors are independent

Third quarter 2022 earnings: Revenues in line with analyst expectations

Novozymes A/S Provides Earnings Guidance for the Year 2022

Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study

A Look At The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022